Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial | Synapse
January 21, 2024Open Access
Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
For the Portuguese, Spanish translations and plain language summary of the abstract see Supplementary Materials section.